HairClone Featured In Consulting Room Article

One of the most fascinating companies in the hair restoration industry, HairClone, has been featured in the latest edition of the UK’s Consulting Room online magazine. The article features commentary from HairClone CEO Paul Kemp PhD and Medical Director Dr. Bessam Farjo.

The article byLorna Jacksonis very detail oriented and provides a comprehensive look at what HairClone aims to bring to the world. Topics covered in the write-up include: HairClone’s banking/cloning/implantation process, the clinical partner program, innovative regulatory designation under UK’s “Specials”, and HairClone’s goals for implementation. I recommend giving the whole article a read-through.

Most of the frequent readers of Follicle Thought already have a basic understanding of HairClone’s strategy and so I will outline here the most interesting details shared in this new HairClone feature:

  • HairClone plans to initially develop a cellular therapy which will “rejuvenate” miniaturizing hair follicles by injecting cloned dermal papilla cells into the scalp. The DP cells will then migrate into hair follicles and help to normalize the anagen or growth cycle of the follicles. The company also plans to develop a “second generation” therapy which would include the culturing of epithelial cells along with the dermal papilla cells to induce hair regeneration. In other words, the sprouting of complete new hairs aka neogenesis.

    Dr. Bessam Farjo explained in the article:A treatment that could rejuvenate existing hair is more attainable, because we now realise, through years of global research that hair loss is a very complicated issue, with multiple factors involved. Whether we get to the stage where we can ‘magically grow hair’, I don’t know, but if we start with the rejuvenating process we could learn so much from that.”

  • Patients in the UK could begin to receive cloned DP cell treatments in 2019 under the “Specials” designation. This is also inclusive to patients in other countries who receive authorization from a HairCloneclinical partnerto receive the expanded cell injections, however the treatments must take place in the UK. The hair follicle banking service, where a sample of a patient’s hair follicles are extracted and then put into deep-freeze for future use, is expected to launch around the end of 2018.
  • As the DP cell injections begin to be administered to patients in the UK, HairClone is also keen to observe the benefit of combining it with other treatments such as PRP. I thought that was particularly interesting.
  • HairClone expects to refine their cell expansion process over the next several years and hopes to have a defined protocol to bring to a phase 3 trial for full-fledged commercialization in about 5 years time. It’s an ambitious timeline, however depending on results from the initial cell expansion treatments in humans, it’s certainly achievable.

Kudos to Paul Kemp and Dr. Farjo for their ingenious effort at HairClone to “make hair-loss history”, as they say in their company tagline. It’s exciting to think of the possibilities that could exist from this treatment in such a short period of time. Likewise, we also know that patience is a virtue and it’s best to remain both grounded and optimistic as we await initial efficacy results from a new treatment. Follicle Thought will certainly keep you up to date on the progress of HairClone’s cell expansion services in the coming months and I expect to share an update on HairClone’s crowdfunding campaign within the next few weeks.

To read the full article published in the Consulting Room magazine, pleaseclick here. HairClone is featured on pages 28-30 of the magazine itself.

43岁的评论on “HairClone Featured In Consulting Room Article

  1. Were you able to see the point that likely in 2019, if you visit a HairClone clinical partner and then travel to UK, you will be able to receive the injections??

  2. Re Hairguy: Please read up on other HairClone articles on Follicle Thought and also the new Consulting Room article which is linked in this story.

    HairClone is able to provide cultured DP cell treatments to patients in the UK under special provision. The treatment has to be deemed safe and produced in a top notch facility. It’s all good news. I understand you are frustrated and I wish you well, I also think understanding this news more clearly could be supportive.

    • Yes admin, I understand that they need to be safe before treating. My question is why do they need to wait 5 more years to start a phase 3 when they are capable of treating people this year? It’s just strange that these companies all prolong their trials or fail. Anywho, there is nothing we can do but wait. I give up though because my treatments are not holding up any more in effectiveness. So by the time this comes to market I’ll be a nw6. If this can grow back all my hair, great but I don’t see it doing that. I do appreciate this blog and all that you do admin. I just had to voice my opinion as a veteran hair loss treatment user. It just would be nice one morning to see a company show a full regrowth of nw6 to nw1 or nw2, or just even some real thick density, not 10 hairs that you have to investigate to see if it’s not a photoshop or combover haha.

      • Answers:
        HairClone plans to refine iterations of their cellular protocol through trial-and-improvement using the “specials” provision. They want to get the best protocol identified and then put that version into a trial.

        I don’t know of any company that prolongs their trials unless: 1) they need investment money to carry out the trial or 2) they are trying to improve their therapy in the interim.

        Dare to dream, there are treatments and combinations of treatments which can create the significant results. I realize the road has been long for some, stay grateful the best you can. Best wishes

    • The individual comments were not deleted, I had deleted one previous comment and that caused all “replies” to that comment to be deleted as well automatically.

      Generally, I do not delete comments after they are approved, but in some cases it happens.

      I have now gone back and manually added all of the other comments. All is well

  3. Dear Admin,
    What does it mean when it says under special provision? I guess many of your followers are already gone far in the hair miniaturization process (just as myself), waiting few more years for replicel (I think delayed communication is never a good sign, I wish fate proves me wrong), all in all, I may become too bald for any satisfying esthetical improvment with such treatment.
    How can we become part of this special provision? As well as when and where
    Thanks.

  4. Is there any indication on 1) how much this rejuvenation treatment may cost? or 2) How much the follicle storing would cost?
    Thanks for another encouraging update!

    • I don’t believe those figures are announced yet.

  5. Hey man good find!

    Comments:
    This seems like an improved protocol of rch-01 which may lead to actual cloning. I like hairclone as a company. They are the backup if rch-01 fails and they are also a backup for tsuji and alexey. And it is always good to have a backup.
    It is really a shame that the funding still stuck at 16.67% I think the last time i checked it was the same and that is 1 or 2 month ago

    Questions:
    Do you have any relation to Hairclone? (I do not mean if you advertise them i mean if you are in any position to get your questions answered by them)

    I did not quite get this one:
    “HairClone are intending to launch
    the banking service around the end
    of the year and hope to provide their
    cell expansion service in 2019. ”
    Does this mean 2019 they start their rch-01 like treatment?
    Or does that mean 2019 they are able to start trials since they are able to multiply dp cells (which i thought they allready figured out)?

    • It comes down to understanding what is available under the special United Kingdom regulatory provision. Here’s a synopsis:

      In the UK a doctor can prescribe an unlicensed treatment (a treatment that has not gone through phase 1-3 trials) if it is deemed to be created safely. This is how patients in the UK could receive the cultured cell treatment before it goes through the trial process under the UK special provision designation.

    • I’d recommend contacting the local doctor of your preference and suggest they get in touch with HairClone! Great idea

      • Why cant I go to the UK and get a doctor of theirs? I don’t have a doctor and they are pretty much all clueless about this treatment.

        • I did not say you couldn’t go to the UK and consult with the Farjo doctors. If you have the means to do so please contact them about it.

  6. I’ve taken a look at the Hairclone site. So this is confusing. They say they still nede to figure out inductivity/ How are they supposed to offer this next year?

    Also, isn’t this process just like Replicel? Isn’t there a patent issue? and won’t this method immunize the hair against future loss like Replicel claims?

    Is there any way for you to get them to maybe doo an interview with you and clarify these questions?

  7. Hi Admin

    Thanks for your hard work, it’s appreciated above words.

    Their initial projekts method sounds a bit like Replicels, where those it differentiate?

    • I appreciate you taking the time to say thank you. I’m glad this site is useful for you.

      简而言之,有许多细胞在真皮papilla and even if Replicel used DP cells (which they do not, Replicel uses dermal sheath cup cells) the two companies treatments could be far different. HairClone are choosing their own proprietary batch of cells to use and expand.

  8. @Rob
    希望Replicel复制和注入国防部indirectly re-create dermal papilla cells because it seems that Replicel could not replicate dermal papilla cells and DSCC is a substitution. This Hair-clone, if works, would be the best and dump Replicel’s business into the dust bin, simply because, we need Dermal Papilla Cells for our hair follicles, not DSCC.
    Correct me if I am wrong.

    @Admin
    Do you think that, this is a much much much better version of Replicel and once they succeeds, Replicel stands no chance to win ?

  9. Dear admin,

    Where can we find more details or effective results about “rejuvenation”? And a short description of this process?
    Regards

    • This Consulting Room article alludes to how it works but not in great detail, it’s the best I know of for now.

  10. Kira, would this also immunize the hair against further loss?

    Unfortunately they don’t have an email address on their site.

    Admin, do you have any means of contacting them for an interview? If this is available next year this would be huge.

    • I don’t have plans to do an interview with them for now, they are working on things and I don’t believe there is anything to share currently. When news is available I will publish it. I might suggest you have a look at all of the previous HairClone articles on FT if haven’t done so.

  11. @admin,

    Do they have any trial results regarding the cloned DP cells, like Replicel ‘s phase 1 ?

    • Not yet. Should be starting to treat humans in 2019.

  12. @admin
    所以他们开始mass-treating humans without any small-scale safety trial ? Kinda weird

    • It will not be a mass treatment, it will be on a smaller scale. A treatment of cultured hair follicle cells has been shown to be safe in humans previously multiple times, I am sure this is taken into account by the regulatory authorities.

  13. Replicel’s is a big fat liar in Biojapan Conference. What do you think about this topic and the Admin? Be honest with me. Only 5% improvements. Husband was lying

      • I believe during the recent conference a Shiseido exec mentioned that the RCH-01 product previously demonstrated a 5% increase in density in Replicel’s original trial, this is my guess.

        • By original, you mean latest trial right? That would be below expectations considering that previous trial did better than 5% I think. They assume they would have optimized the number of cells and number of injections and achieve better result. Are you preparing an update on this admin? thx.

          • No, actually I mean the trial Replicel did in 2011.

  14. @ADMIN can your source of Shiseido confirm whether the trials of RCH-01 have finished? Obviously on the BioJapan Masashi Ogo said, that they Are only at The half time of their trials so they haven’t even finished… is that true?

    • If that’s what he said at the conference it sounds reasonable to me.

留下一个回复GeorgesCancel reply

Your email address will not be published.